316 related articles for article (PubMed ID: 28499383)
1. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
Alves LF; da Silva RF; Cagnon VHA
Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
[TBL] [Abstract][Full Text] [Related]
7. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
8. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
[TBL] [Abstract][Full Text] [Related]
9. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
10. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
[TBL] [Abstract][Full Text] [Related]
11. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.
da Silva RF; Dhar D; Raina K; Kumar D; Kant R; Cagnon VHA; Agarwal C; Agarwal R
Sci Rep; 2018 Jun; 8(1):9540. PubMed ID: 29934570
[TBL] [Abstract][Full Text] [Related]
14. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
[TBL] [Abstract][Full Text] [Related]
17. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
Singh RP; Raina K; Sharma G; Agarwal R
Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
[TBL] [Abstract][Full Text] [Related]
18. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE
Prostate; 2007 May; 67(6):661-73. PubMed ID: 17342743
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]